BioAge Labs, Inc. is a clinical-stage biotechnology company dedicated to extending human healthspan by developing therapies that target the molecular mechanisms of aging. Founded in 2015 and headquartered in Richmond, California, BioAge leverages a comprehensive multi-omics platform to identify and validate biomarkers of aging. By mining longitudinal human data and integrating transcriptomics, proteomics, and metabolomics, the company seeks to uncover key pathways that drive age-related diseases and translate these insights into novel therapeutics.
The company’s lead programs focus on small molecule drug candidates designed to modulate fundamental hallmarks of aging, such as inflammation, cellular senescence, and metabolic dysfunction. BioAge’s pipeline includes several clinical-stage assets in development for age-associated conditions, including cardiovascular disease, metabolic disorders, and immune decline. These programs are being evaluated in Phase 1 and Phase 2 clinical trials, with each candidate selected based on human aging data to maximize the likelihood of clinical success and broad applicability across multiple disease indications.
In addition to internal drug development, BioAge offers its proprietary BioAge Intelligence Platform as a collaborative service to pharmaceutical and biotechnology partners. This platform harnesses advanced machine learning algorithms and real-world human data to accelerate target discovery, biomarker identification, and patient stratification. Partnerships with leading academic institutions and industry players have enabled BioAge to expand its research footprint and co-develop next-generation aging therapies on a global scale.
Leadership at BioAge is headed by co-founder and CEO Kristen Fortney, Ph.D., whose expertise in computational biology and biomarker research underpins the company’s data-driven approach. Supporting the executive team are seasoned professionals in clinical development, regulatory affairs, and finance, bringing deep experience from both biotech startups and large pharmaceutical firms. With operations primarily in the United States and strategic collaborations in Europe, BioAge Labs remains focused on delivering innovative aging interventions to improve long-term health outcomes worldwide.
AI Generated. May Contain Errors.
Free BIOA Stock Alerts